| Case Name | Date Filed | Judge | Drug | Patent No(s). |
|---|---|---|---|---|
| Teijin Ltd. v. Torrent Pharms. Ltd., 18-0987 (D. Del.) | 2-Jul-18 | Vacant Judgeship (2017) | Uloric® (febuxostat tablets) | 7,361,676, 8,372,872, 9,107,912 |
| Dr. Reddy’s Labs. Inc. v. Pozen Inc., IPR2018-01341 (PTAB) | 2-Jul-18 | N/A | Vimovo® (esomeprazole magnesium / naproxen delayed-release tablets) | 9,393,208 |
| Boehringer Ingelheim Pharms., Inc. v. Apotex Inc., 18-11350 (D.N.J.) | 3-Jul-18 | Hon. Michael A. Shipp | Gilotrif® (afatinib tablets) | 8,426,586 |
| Celgene Corp. v. Amneal Pharms. LLC, 18-11358 (D.N.J.) | 3-Jul-18 | Hon. Michael A. Shipp | Otezla® (apremilast tablets) | 6,962,940, 7,427,638, 7,659,302, 7,893,101, 8,455,536, 9,018,243 |
| Celgene Corp. v. Aurobindo Pharma Ltd., 18-1005 (D. Del.) | 6-Jul-18 | Hon. Richard G. Andrews | Otezla® (apremilast tablets) | 6,962,940, 7,208,516, 7,427,638, 7,659,302, 7,893,101, 8,455,536, 8,802,717, 9,018,243, 9,872,854 |
| Cosmo Technologies Ltd. v. Actavis Labs. FL, Inc., 18-1006 (D. Del.) | 6-Jul-18 | Hon. Leonard P. Stark | Uceris® (budesonide extended-release tablets) | 9,737,489, 9,592,203 |
| Mylan Pharms. Inc. v. Anacor Pharms., Inc., IPR2018-01358 (PTAB) | 6-Jul-18 | N/A | Kerydin® (tavaborole topical solution) | 9,549,938 |
| Mylan Pharms. Inc. v. Anacor Pharms., Inc., IPR2018-01359 (PTAB) | 6-Jul-18 | N/A | Kerydin® (tavaborole topical solution) | 9,566,289 |
| Horizon Pharma, Inc. v. Alkem Labs. Ltd., 18-1014 (D. Del.) | 9-Jul-18 | Hon. Leonard P. Stark | Duexis® (ibuprofen / famotidine tablets) | 8,067,033, 8,067,451, 8,309,127, 8,318,202, 8,449,910, 8,501,228 |
| Celgene Corp. v. Sandoz, Inc., 18-1764 (D. Col.) | 10-Jul-18 | Hon. William J. Martinez | Otezla® (apremilast tablets) | 6,962,940, 7,208,516, 7,427,638, 7,659,302, 7,893,101, 8,455,536, 8,802,717, 9,018,243, 9,872,854 |
| Celgene Corp. v. Lotus Pharm. Co., Ltd., 18-11518 (D.N.J.) | 10-Jul-18 | Hon. Susan D. Wigenton | Revlimid® (lenalidomide capsules) | 7,977,357, 8,193,219, 8,431,598 |
| Mylan Pharms. Inc. v. Anacor Pharms., Inc., IPR2018-01360 (PTAB) | 10-Jul-18 | N/A | Kerydin® (tavaborole topical solution) | 9,566,290 |
| Mylan Pharms. Inc. v. Anacor Pharms., Inc., IPR2018-01361 (PTAB) | 10-Jul-18 | N/A | Kerydin® (tavaborole topical solution) | 9,572,823 |
| Eli Lilly and Co. v. Torrent Pharms. Ltd., 18-11543 (D.N.J.) | 11-Jul-18 | Hon. William H. Walls | Cialis® (tadalafil tablets) | 6,943,166 |
| Celgene Corp. v. Pharmascience Inc., 18-11545 (D.N.J.) | 11-Jul-18 | Hon. Michael A. Shipp | Otezla® (apremilast tablets) | 6,962,940, 7,427,638, 7,659,302, 7,893,101, 8,455,536, 9,018,243 |
| Celgene Corp. v. Amneal Pharms. LLC, 18-1032 (D. Del.) | 12-Jul-18 | Hon. Richard G. Andrews | Otezla® (apremilast tablets) | 6,962,940, 7,427,638, 7,659,302, 7,893,101, 8,455,536, 9,018,243 |
| H. Lundbeck A/S v. Apicore US LLC, 18-1034 (D. Del.) | 12-Jul-18 | Hon. Leonard P. Stark | Trintellix® (vortioxetine hydrobromide tablets) | 7,144,884, 8,476,279, 8,722,684, 8,969,355, 9,227,946, 9,861,630 |
| Novartis Pharms. Corp. v. Apotex Inc., 18-1038 (D. Del.) | 13-Jul-18 | Hon. Leonard P. Stark | Gilenya® (fingolimod capsules) | 9,187,405 |
| Novartis Pharms. Corp. v. Teva Pharms. USA, Inc., 18-1039 (D. Del.) | 13-Jul-18 | Hon. Leonard P. Stark | Gilenya® (fingolimod capsules) | 9,187,405 |
| Novartis Pharms. Corp. v. Sun Pharm. Indus., Ltd., 18-1040 (D. Del.) | 13-Jul-18 | Hon. Leonard P. Stark | Gilenya® (fingolimod capsules) | 9,187,405 |
| Mylan Pharms. Inc. v. Biogen MA, Inc., IPR2018-01403 (PTAB) | 13-Jul-18 | N/A | Tecfidera® (dimethyl fumarate delayed-release capsules) | 8,399,514 |
| Takeda Pharm. Co. Ltd. v. Zydus Pharms. (USA) Inc., 18-11792 (D.N.J.) | 18-Jul-18 | Hon. Freda L. Wolfson | Prevacid® SoluTab™ (lansoprazole delayed-release orally-disintegrating tablets) | 9,901,546 |
| Genzyme Corp. v. Gland Pharma Ltd., 18-1071 (D. Del.) | 19-Jul-18 | Hon. Kent A. Jordan | Mozobil® (plerixafor for injection) | RE42,152, 7,897,590, 6,987,102 |
| Eagle Pharms., Inc. v. Hospira, Inc., 18-1074 (D. Del.) | 19-Jul-18 | Hon. Leonard P. Stark | Bendeka® (bendamustine HCl for injection) | 9,572,887, 10,010,533, 9,034,908, 9,144,568, 9,597,397, 9,597,398, 9,597,399, 9,000,021, 9,579,384 |
| Perrigo Research & Development Co. v. GlaxoSmithKline Consumer Healthcare, L.P., 18-11835 (D.N.J.) | 29-Jul-18 | Hon. Brian R. Martinotti | Nicorette® (nicotine polacrilex lozenge) | 8,501,164, 8,940,772 |
| Adare Pharms., Inc. v. Teva Pharms. Int’l GMBH, 18-1079 (D. Del.) | 20-Jul-18 | Hon. Mitchell S. Goldberg | Amrix® (cyclobenzaprine HCl extended-release capsules) | 9,399,025, 9,375,410 |
| Mallinckrodt Hospital Products IP Ltd. v. B. Braun Medical Inc., 18-1090 (D. Del.) | 24-Jul-18 | Hon. Leonard P. Stark | Ofirmev® (acetaminophen for injection) | 9,987,238 |
| Osi Pharms., LLC v. Shilpa Medicare Ltd., 18-1096 (D. Del.) | 25-Jul-18 | Hon. Gregory M. Sleet | Tarceva® (erlotinib HCl tablets) | 6,900,221 |
| AstraZeneca Pharms. LP v. Accord Healthcare, Inc., 18-12051 (D.N.J.) | 25-Jul-18 | Hon. Renee Marie Bumb | Faslodex® (fulvestrant for injection) | 6,774,122, 7,456,160, 8,329,680, 8,466,139 |
| Shire-NPS Pharms., Inc. v. Par Pharm. Cos., Inc., 18-1115 (D. Del.) | 28-Jul-18 | Hon. Richard G. Andrews | Gattex® (teduglutide for injection) | 9,968,655, 9,968,656, 9,968,658, 9,974,835, 9,974,837, 9,981,014, 9,981,016, 9,987,334 |
| Santen Pharm. Co. Ltd., Micro Labs Ltd., 18-12333 (D.N.J.) | Aug. 1, 2018 | Hon. Brian R. Martinotti | Zioptan® (tafluprost ophthalmic solution) | 9,999,593 |
| Eli Lilly and Co. v. Umedica Labs. Pvt., Ltd., 18-12385 (D.N.J.) | Aug. 2, 2018 | Hon. William H. Walls | Cialis® (tadalafil tablets) | 6,943,166 |
| Neptune Generics, LLC v. Corcept Therapeutics, Inc., IPR2018-01494 (PTAB) | Aug. 2, 2018 | N/A | Korlym® (mifepristone tablets) | 8,921,348 |
| Dr. Reddy’s Labs., Inc. v. Celgene Corp., IPR2018-01504 (PTAB) | Aug. 3, 2018 | N/A | Revlimid® (lenalidomide capsules) | 9,056,120 |
| Dr. Reddy’s Labs., Inc. v. Celgene Corp., IPR2018-01507 (PTAB) | Aug. 3, 2018 | N/A | Revlimid® (lenalidomide capsules) | 8,404,717 |
| Dr. Reddy’s Labs., Inc. v. Celgene Corp., IPR2018-01509 (PTAB) | Aug. 3, 2018 | N/A | Revlimid® (lenalidomide capsules) | 7,189,740 |
| Fresenius Kabi USA, LLC v. Custopharm, Inc., 18-0665 (W.D. Tex.) | Aug. 6, 2018 | Hon. Lee Yeakel | Naropin® (ropivacaine HCl for injection) | 8,118,802, 8,162,915 |
| Taro Pharms. U.S.A., Inc. v. Glenmark Pharms. Ltd., 18-12569 (D.N.J.) | Aug. 8, 2018 | Hon. John Michael Vazquez | Topicort® (desoximetasone topical spray) | 8,277,780, 8,715,624 |
| Horizon Therapeutics, LLC v. Par Pharm., Inc., 18-1224 (D. Del.) | Aug. 10, 2018 | Hon. Richard G. Andrews | Ravicti® (glycerol phenylbutyrate oral liquid) | 8,642,012 |
| Allergan, Inc. v. Saptalis Pharms., LLC, 18-1231 (D. Del.) | Aug. 10, 2018 | Hon. Leonard P. Stark | Restasis® (cyclosporine ophthalmic emulsion) | 8,633,162, 8,642,556 |
| AstraZeneca LP v. Hisun Pharm. (Hangzhou) Co., Ltd., 18-1232 (D. Del.) | Aug. 10, 2018 | Hon. Richard G. Andrews | Brilinta® (ticagrelor tablets) | RE46,276, 7,250,419, 7,265,124 |
| Boehringer Ingelheim Pharms., Inc. v. Lupin Atlantis Holdings SA, 18-12663 (D.N.J.) | Aug. 10, 2018 | Hon. Brian R. Martinotti | Spiriva® HandiHaler® (tiotropium bromide inhalation powder) | 7,070,800, 7,694,676 |
| Athenex Pharma Solutions, LLC v. Par Pharm., Inc., 18-0896 (W.D.N.Y.) | Aug. 13, 2018 | Hon. Geoffrey Crawford | Vasostrict® (vasopressin injection) | 9,375,478, 9,687,526, 9,744,209, 9,744,239, 9,750,785, 9,937,223 |
| Shionogi Inc. v. Zydus Pharms. (USA) Inc., 18-12898 (D.N.J.) | Aug. 16, 2018 | Hon. Brian R. Martinotti | Fortamet® (metformin HCl extended-release tablets) | 6,790,459, 6,866,866 |
| Par Pharm., Inc. v. Horizon Therapeutics, LLC, IPR2018-01550 (PTAB) | Aug. 21, 2018 | N/A | Ravicti® (glycerol phenylbutyrate oral liquid) | 9,561,197 |
| Valeant Pharms. Int’l v. Actavis Labs. FL., Inc., 18-1288 (D. Del.) | Aug. 22, 2018 | Hon. Leonard P. Stark | Uceris® (budesonide extended-release tablets) | 10,052,286 |
| Biofrontera Inc. v. Dusa Pharms., Inc., IPR2018-01585 (PTAB) | Aug. 22, 2018 | N/A | Levulan® (aminolevulinic acid HCl topical solution) | 8,216,289 |
| Biofrontera Inc. v. Dusa Pharms., Inc., IPR2018-01585 (PTAB) | Aug. 22, 2018 | N/A | Levulan® (aminolevulinic acid HCl topical solution) | 9,723,991 |
| Insys Therapeutics, Inc. v. Teva Pharms. USA, Inc., 18-1308 (D. Del.) | Aug. 23, 2018 | Hon. Colm F. Connolly | Subsys® (fentanyl sublingual spray) | 8,486,972, 8,486,973, 8,835,459, 8,835,460, 9,241,935, 9,289,387, 9,642,797, 9,642,844 |
| Biogen Int’l Gmbh v. Windlas Healthcare, Pvt. Ltd., 18-1361 (D. Del.) | Aug. 31, 2018 | Hon. Leonard P. Stark | Tecfidera® (dimethyl fumarate delayed-release capsules) | 6,509,376, 7,320,999 |
| Celgene Corp. v. West-ward Pharms. Int’l Ltd., 18-13477 (D.N.J.) | Aug. 31, 2018 | Hon. Susan D. Wigenton | Thalomid® (thalidomide capsules) | 6,315,720, 6,561,977, 6,755,784, 6,869,399, 7,141,018, 7,230,012, 7,959,566, 8,315,886, 8,626,531 |
| Sumitomo Dainippon Pharma Co., Ltd. v. Piramal Healthcare UK Ltd., 18-13478 (D.N.J.) | Aug. 31, 2018 | Hon. Stanley R. Chesler | Latuda® (lurasidone HCl tablets) | 9,815,827, 9,907,794 |
| Symed Labs Ltd. v. Amneal Pharms. LLC, 18-13628 (D.N.J.) | Sept. 6, 2018 | Hon. Claire C. Cecchi | linezolid tablets | 7,351,824, 7,429,661 |
| Valeant Pharms. North America LLC v. Zydus Pharms. (USA) Inc., 18-13635 (D.N.J.) | Sept. 6, 2018 | Hon. Peter G. Sheridan | Jublia® (efinaconazole topical solution) | 7,214,506, 8,039,494, 8,486,978, 9,302,009, 9,566,272, 9,662,394, 9,861,698, 9,877,955 |
| Amgen Inc. v. Emcure Pharms. Ltd., 18-1393 (D. Del.) | Sept. 7, 2018 | Hon. Mitchell S. Goldberg | Sensipar® (cinacalcet tablets) | 9,375,405 |
| Biodelivery Sciences Int’l, Inc. v. Alvogen Pb Research & Development LLC, 18-1395 (D. Del.) | Sept. 7, 2018 | Hon. Colm F. Connolly | Belbuca® (buprenorphine buccal film) | 8,147,866, 9,655,843, 9,901,539 |
| Valeant Pharms. North America LLC v. Aurobindo Pharma USA Inc., 18-13693 (D.N.J.) | Sept. 7, 2018 | Hon. Peter G. Sheridan | Jublia® (efinaconazole topical solution) | 7,214,506, 8,039,494, 8,486,978, 9,302,009, 9,566,272, 9,662,394, 9,861,698, 9,877,955 |
| Valeant Pharms. North America LLC v. Solaris Pharma Corp., 18-13695 (D.N.J.) | Sept. 7, 2018 | Hon. Peter G. Sheridan | Jublia® (efinaconazole topical solution) | 7,214,506, 8,039,494, 8,486,978, 9,302,009, 9,566,272, 9,662,394, 9,861,698, 9,877,955 |
| Valeant Pharms. North America LLC v. Strides Pharma Inc., 18-13696 (D.N.J.) | Sept. 7, 2018 | Hon. Peter G. Sheridan | Jublia® (efinaconazole topical solution) | 7,214,506, 8,039,494, 8,486,978, 9,302,009, 9,566,272, 9,662,394, 9,861,698, 9,877,955 |
| Valeant Pharms. North America LLC v. Lupin Ltd., 18-13700 (D.N.J.) | Sept. 7, 2018 | Hon. Peter G. Sheridan | Jublia® (efinaconazole topical solution) | 7,214,506, 8,039,494, 8,486,978, 9,302,009, 9,566,272, 9,662,394, 9,861,698, 9,877,955 |
| Valeant Pharms. North America LLC v. Par Pharm., Inc., 18-13701 (D.N.J.) | Sept. 7, 2018 | Hon. Peter G. Sheridan | Jublia® (efinaconazole topical solution) | 7,214,506, 8,039,494, 8,486,978, 9,302,009, 9,566,272, 9,662,394, 9,861,698, 9,877,955 |
| Valeant Pharms. North America LLC v. Par Pharm., Inc., 18-8221 (S.D.N.Y.) | Sept. 10, 2018 | Hon. Edgardo Ramos | Jublia® (efinaconazole topical solution) | 7,214,506, 8,039,494, 8,486,978, 9,302,009, 9,566,272, 9,662,394, 9,861,698, 9,877,955 |
| Mylan Pharms. Inc. v. Sanofi-Aventis Deutschland Gmbh, IPR2018-01670 (PTAB) | Sept. 10, 2018 | N/A | Lantus® SoloStar® (insulin glargine recombinant for injection), Apidra® SoloStar® (insulin glulisine recombinant for injection), Toujeo® (Insulin glargine recombinant subcutaneous solution), Soliqua® (insulin glargine / lixisenatide subcutaneous solution), Admelog® Solostar® (insulin lispro for injection) | 8,679,069 |
| Mylan Pharms. Inc. v. Sanofi-Aventis Deutschland Gmbh, IPR2018-01675 (PTAB) | Sept. 10, 2018 | N/A | Lantus® SoloStar® (insulin glargine recombinant for injection), Apidra® SoloStar® (insulin glulisine recombinant for injection), Toujeo® (Insulin glargine recombinant subcutaneous solution), Soliqua® (insulin glargine / lixisenatide subcutaneous solution), Admelog® Solostar® (insulin lispro for injection) | 8,603,044 |
| Mylan Pharms. Inc. v. Sanofi-Aventis Deutschland Gmbh, IPR2018-01676 (PTAB) | Sept. 10, 2018 | N/A | Lantus® SoloStar® (insulin glargine recombinant for injection), Apidra® SoloStar® (insulin glulisine recombinant for injection), Toujeo® (Insulin glargine recombinant subcutaneous solution), Soliqua® (insulin glargine / lixisenatide subcutaneous solution), Admelog® Solostar® (insulin lispro for injection) | 8,603,044 |
| Mylan Pharms. Inc. v. Sanofi-Aventis Deutschland Gmbh, IPR2018-01677 (PTAB) | Sept. 10, 2018 | N/A | Lantus® SoloStar® (insulin glargine recombinant for injection), Apidra® SoloStar® (insulin glulisine recombinant for injection), Toujeo® (Insulin glargine recombinant subcutaneous solution), Soliqua® (insulin glargine / lixisenatide subcutaneous solution), Admelog® Solostar® (insulin lispro for injection) | 8,992,486 |
| Mylan Pharms. Inc. v. Sanofi-Aventis Deutschland Gmbh, IPR2018-01678 (PTAB) | Sept. 10, 2018 | N/A | Lantus® SoloStar® (insulin glargine recombinant for injection), Apidra® SoloStar® (insulin glulisine recombinant for injection), Toujeo® (Insulin glargine recombinant subcutaneous solution), Soliqua® (insulin glargine / lixisenatide subcutaneous solution), Admelog® Solostar® (insulin lispro for injection) | 8,992,486 |
| Mylan Pharms. Inc. v. Sanofi-Aventis Deutschland Gmbh, IPR2018-01679 (PTAB) | Sept. 10, 2018 | N/A | Lantus® SoloStar® (insulin glargine recombinant for injection), Apidra® SoloStar® (insulin glulisine recombinant for injection), Toujeo® (Insulin glargine recombinant subcutaneous solution), Soliqua® (insulin glargine / lixisenatide subcutaneous solution), Admelog® Solostar® (insulin lispro for injection) | 8,992,486 |
| Mylan Pharms. Inc. v. Sanofi-Aventis Deutschland Gmbh, IPR2018-01680 (PTAB) | Sept. 10, 2018 | N/A | Lantus® SoloStar® (insulin glargine recombinant for injection), Apidra® SoloStar® (insulin glulisine recombinant for injection), Toujeo® (Insulin glargine recombinant subcutaneous solution), Soliqua® (insulin glargine / lixisenatide subcutaneous solution), Admelog® Solostar® (insulin lispro for injection) | 9,526,844 |
| Mylan Pharms. Inc. v. Sanofi-Aventis Deutschland Gmbh, IPR2018-01682 (PTAB) | Sept. 10, 2018 | N/A | Lantus® SoloStar® (insulin glargine recombinant for injection), Apidra® SoloStar® (insulin glulisine recombinant for injection), Toujeo® (Insulin glargine recombinant subcutaneous solution), Soliqua® (insulin glargine / lixisenatide subcutaneous solution), Admelog® Solostar® (insulin lispro for injection) | 9,526,844 |
| Mylan Pharms. Inc. v. Sanofi-Aventis Deutschland Gmbh, IPR2018-01684 (PTAB) | Sept. 10, 2018 | N/A | Lantus® SoloStar® (insulin glargine recombinant for injection), Apidra® SoloStar® (insulin glulisine recombinant for injection), Toujeo® (Insulin glargine recombinant subcutaneous solution), Soliqua® (insulin glargine / lixisenatide subcutaneous solution), Admelog® Solostar® (insulin lispro for injection) | 9,604,008 |
| Mylan Pharms. Inc. v. Sanofi-Aventis Deutschland Gmbh, IPR2018-01696 (PTAB) | Sept. 10, 2018 | N/A | Lantus® SoloStar® (insulin glargine recombinant for injection), Apidra® SoloStar® (insulin glulisine recombinant for injection), Toujeo® (Insulin glargine recombinant subcutaneous solution), Soliqua® (insulin glargine / lixisenatide subcutaneous solution), Admelog® Solostar® (insulin lispro for injection) | 9,526,844 |
| Sumitomo Dainippon Pharma Co., Ltd. v. Macleods Pharms. Ltd., 18-13833 (D.N.J.) | Sept. 12, 2018 | Hon. Stanley R. Chesler | Latuda® (lurasidone HCl tablets) | 9,815,827, 9,907,794 |
| Alvogen Pine Brook LLC v. Celgene Corp., IPR2018-01714 (PTAB) | Sept. 12, 2018 | N/A | Revlimid® (lenalidomide capsules) | 7,968,569 |
| Valeant Pharms. North America LLC v. Alkem Labs. Ltd., 18-13905 (D.N.J.) | Sept. 14, 2018 | Hon. Peter G. Sheridan | Jublia® (efinaconazole topical solution) | 7,214,506, 8,039,494, 8,486,978, 9,302,009, 9,566,272, 9,662,394, 9,861,698, 9,877,955 |
| Valeant Pharms. North America LLC v. Alkem Labs. Ltd., 18-13954 (D.N.J.) | Sept. 17, 2018 | Hon. Peter G. Sheridan | Jublia® (efinaconazole topical solution) | 7,214,506, 8,039,494, 8,486,978, 9,302,009, 9,566,272, 9,662,394, 9,861,698, 9,877,955 |
| Duke University v. Akorn, Inc., 18-14035 (D.N.J.) | Sept. 19, 2018 | Hon. Brian R. Martinotti | Latisse® (bimatoprost ophthalmic solution) | 9,579,270 |
| Allergan, Inc. v. Amneal Pharms. LLC, 18-1457 (D. Del.) | Sept. 20, 2018 | Hon. Leonard P. Stark | Restasis® (cyclosporine ophthalmic emulsion) | 8,633,162, 8,642,556 |
| Eagle Pharms., Inc. v. Slayback Pharma LLC, 18-1459 (D. Del.) | Sept. 20, 2018 | Hon. Colm F. Connolly | Bendamustine HCl Injection) | 8,609,707, 9,265,831, 9,572,796, 9,572,797, 10,010,533 |
| Celgene Corp. v. Hetero Labs Ltd., 18-14111 (D.N.J.) | Sept. 20, 2018 | Hon. Esther Salas | Pomalyst® (pomalidomide capsules) | 9,993,467 |
| Bayer Healthcare LLC v. Apotex Inc., 18-1465 (D. Del.) | Sept. 21, 2018 | Hon. Leonard P. Stark | Stivarga® (regorafenib tablets) | 9,957,232 |
| Valeant Pharms. North America LLC v. Acrux DDS Pty Ltd., 18-14194 (D.N.J.) | Sept. 21, 2018 | Hon. Peter G. Sheridan | Jublia® (efinaconazole topical solution) | 7,214,506, 8,039,494, 8,486,978, 9,302,009, 9,566,272, 9,662,394, 9,861,698, 9,877,955 |
| Valeant Pharms. North America LLC v. Apotex Inc., 18-14202 (D.N.J.) | Sept. 21, 2018 | Hon. Peter G. Sheridan | Jublia® (efinaconazole topical solution) | 7,214,506, 8,039,494, 8,486,978, 9,302,009, 9,566,272, 9,662,394, 9,861,698, 9,877,955 |
| Valeant Pharms. North America LLC v. Macleods Pharms. Ltd., 18-14204 (D.N.J.) | Sept. 21, 2018 | Hon. Peter G. Sheridan | Jublia® (efinaconazole topical solution) | 7,214,506, 8,039,494, 8,486,978, 9,302,009, 9,566,272, 9,662,394, 9,861,698, 9,877,955 |
| Valeant Pharms. North America LLC v. Perrigo Pharma Int’l DAC, 18-14207 (D.N.J.) | Sept. 21, 2018 | Hon. Peter G. Sheridan | Jublia® (efinaconazole topical solution) | 7,214,506, 8,039,494, 8,486,978, 9,302,009, 9,566,272, 9,662,394, 9,861,698, 9,877,955 |
| Valeant Pharms. North America LLC v. Slayback Pharma, LLC, 18-14208 (D.N.J.) | Sept. 21, 2018 | Hon. Peter G. Sheridan | Jublia® (efinaconazole topical solution) | 7,214,506, 8,039,494, 8,486,978, 9,302,009, 9,566,272, 9,662,394, 9,861,698, 9,877,955 |
| Valeant Pharms. North America LLC v. Teva Pharms. USA, Inc., 18-14209 (D.N.J.) | Sept. 21, 2018 | Hon. Peter G. Sheridan | Jublia® (efinaconazole topical solution) | 7,214,506, 8,039,494, 8,486,978, 9,302,009, 9,566,272, 9,662,394, 9,861,698, 9,877,955 |
| Valeant Pharms. North America LLC v. Cipla Ltd., 18-14225 (D.N.J.) | Sept. 24, 2018 | Hon. Peter G. Sheridan | Jublia® (efinaconazole topical solution) | 7,214,506, 8,039,494, 8,486,978, 9,302,009, 9,566,272, 9,662,394, 9,861,698, 9,877,955 |
| Valeant Pharms. North America LLC v. KVK-Tech, Inc., Ltd., 18-14298 (D.N.J.) | Sept. 26, 2018 | Hon. Peter G. Sheridan | Jublia® (efinaconazole topical solution) | 7,214,506, 8,039,494, 8,486,978, 9,302,009, 9,566,272, 9,662,394, 9,861,698, 9,877,955 |
| Valeant Pharms. North America LLC v. Mylan Pharms. Inc., 18-14305 (D.N.J.) | Sept. 26, 2018 | Hon. Peter G. Sheridan | Jublia® (efinaconazole topical solution) | 7,214,506, 8,039,494, 8,486,978, 9,302,009, 9,566,272, 9,662,394, 9,861,698, 9,877,955 |
| Adamis Pharms. Corp. v. Belcher Pharms., LLC, 18-2379 (M.D. Fla.) | Sept. 26, 2018 | Hon. William F. Jung | Symjepi® (epinephrine for injection) | 9,283,197, 10,004,700 |
| Celgene Corp. v. Teva Pharms USA, Inc., 18-14366 (D.N.J.) | Sept. 27, 2018 | Hon. Esther Salas | Pomalyst® (pomalidomide capsules) | 9,993,467 |
| Valeant Pharms. North America LLC v. Mylan Pharms. Inc., 18-0184 (N.D.W.V.) | Sept. 26, 2018 | Hon. Irene M. Keeley | Jublia® (efinaconazole topical solution) | 7,214,506, 8,039,494, 8,486,978, 9,302,009, 9,566,272, 9,662,394, 9,861,698, 9,877,955 |
| Valeant Pharms. North America LLC v. KVK-Tech, Inc., Ltd., 18-4195 (E.D. Pa.) | Sept. 27, 2018 | Hon. Paul S. Diamond | Jublia® (efinaconazole topical solution) | 7,214,506, 8,039,494, 8,486,978, 9,302,009, 9,566,272, 9,662,394, 9,861,698, 9,877,955 |
| Alembic Pharms. Ltd. v. GlaxoSmithKline LLC, 18-1513 (D. Del.) | Sept. 28, 2018 | Hon. Richard G. Andrews | Lamictal® XR (lamotrigine extended-release tablets) | 8,637,512, 9,144,547 |
| Valeant Pharms. North America LLC v. Amneal Pharms. LLC, 18-14468 (D.N.J.) | Sept. 28, 2018 | Hon. Peter G. Sheridan | Jublia® (efinaconazole topical solution) | 7,214,506, 8,039,494, 8,486,978, 9,302,009, 9,566,272, 9,662,394, 9,861,698, 9,877,955 |
Related Attorneys
Partner
